A cost variation analysis of chronic obstructive pulmonary disorder medications in the Indian market concerning Jan Aushadhi medications and their branded counterparts
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20251407Keywords:
Jan Aushadhi, COPD, Generic medications, Cost analysis, Out of pocket expenditure, Cost minimizationAbstract
Medications and pharmaceutical expenses constitute a significant portion of out-of-pocket health expenditures for households in India, posing a substantial financial burden. The objective of this study was to assess the cost differences among drugs utilized in the treatment of chronic obstructive pulmonary disorder (COPD), specifically comparing those available at Jan Aushadhi pharmacies with various branded drug formulations. In the study, we calculated the cost differences (in Indian Rupees), cost ratios, and cost variations by contrasting the cost of generic Jan Aushadhi medications with the most expensive and least expensive branded medications in the same category. Our study revealed that the price of branded drugs prescribed for obstructive pulmonary conditions was higher than that of generic drugs purchased from Jan Aushadhi pharmacies except in the case of doxophylline 400 mg tablet. The highest cost difference was observed in the combination drug of formoterol 6 mcg + fluticasone propionate 250 mcg inhaler (740 and 290). Cost variance and cost ratio were highest in salbutamol 4 mg tablets (2386%) and (24.86) respectively. Findings indicate that across all classes of drugs investigated, the costs associated with generic drugs in Jan Aushadhi centers were markedly lower than those associated with branded drugs. Medications offered by Jan Aushadhi pharmacies are more cost-effective than their branded equivalents, rendering COPD treatment more accessible and affordable for individuals with limited financial means.
Metrics
References
Devine JF. Chronic Obstructive Pulmonary Disease: An Overview. Am Health Drug Benefits. 2008;1(7):34-42.
Cukic V, Lovre V, Dragisic D, Ustamujic A. Asthma and Chronic Obstructive Pulmonary Disease (COPD) – Differences and Similarities. Mater Sociomed. 2012;24(2):100-5. DOI: https://doi.org/10.5455/msm.2012.24.100-105
Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017;390(10100):1211-59. DOI: https://doi.org/10.1016/S0140-6736(17)32154-2
Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob Health Epidemiol Genom. 2018;3:e4. DOI: https://doi.org/10.1017/gheg.2018.1
Walia GK, Vellakkal R, Gupta V. Chronic Obstructive Pulmonary Disease and its Non-Smoking Risk Factors in India. COPD: J Chronic Obstruct Pulmonary Dis. 2016;13(2):251-61. DOI: https://doi.org/10.3109/15412555.2015.1057807
Zhang X, Zhu X, Wang X, Wang L, Sun H, Yuan P, et al. Association of Exposure to Biomass Fuels with Occurrence of Chronic Obstructive Pulmonary Disease in Rural Western China: A Real-World Nested Case-Control Study. COPD. 2023;18:2207-24. DOI: https://doi.org/10.2147/COPD.S417600
Daniel RA, Aggarwal P, Kalaivani M, Gupta SK. Prevalence of chronic obstructive pulmonary disease in India: A systematic review and meta-analysis. Lung India. 2021;38(6):506-13. DOI: https://doi.org/10.4103/lungindia.lungindia_159_21
Gupta D, Agarwal R, Aggarwal AN, Maturu VN, Dhooria S, Prasad KT, et al. Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India. 2013;30(3):228-67. DOI: https://doi.org/10.4103/0970-2113.116248
Selvaraj S, Farooqui HH, Karan A. Quantifying the financial burden of households’ out-of-pocket payments on medicines in India: a repeated cross-sectional analysis of National Sample Survey data, 1994–2014. BMJ Open. 2018;8(5):e018020. DOI: https://doi.org/10.1136/bmjopen-2017-018020
Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, Government of India. Pharmaceuticals & Medical Devices Bureau of India. Available at: http://janaushadhi.gov.in/pmjy.aspx. Accessed on 12 February 2025.
Ministry of Chemicals and Fertilizers. Government to open 25000 Jan Aushadhi Kendras to make medicines available at affordable prices. Available at: https://pib.gov.in/pib.gov.in/Pressreleaseshare.aspx?PRID=1948866. Accessed on 12 February 2025.
CIMS. Search Drug Information. Available at: https://www.mims.com/india/drug. Accessed on 12 February 2025.
Hindustan Times. Out-of-pocket health expenditure in India: Inter-state variations. 2023. Available at: https://www.hindustantimes.com/ht-insight/public-health/outofpocket-health-expenditure-in-india-inter-state-variations-101691992454616.html. Accessed on 12 February 2025.
George T, Baliga MS. Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study. Cureus. 2021;13(11):e19231. DOI: https://doi.org/10.7759/cureus.19231
Gauthaman J. A cost analysis and availability scenario of drugs and oral care products prescribed for common oral conditions with reference to the current Indian market prices, Jan Aushadhi, and the state medical commissions. J Family Med Prim Care. 2022;11(5):2134-8. DOI: https://doi.org/10.4103/jfmpc.jfmpc_1538_21
Mukherjee K. A Cost Analysis of the Jan Aushadhi Scheme in India. Int J Health Policy Management. 2017;6(5):253-6. DOI: https://doi.org/10.15171/ijhpm.2017.02
Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, et al. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Med. 2019;16(3):e1002763. DOI: https://doi.org/10.1371/journal.pmed.1002763
Ledan S. Discussing Brand Versus Generic Medications. US Pharm. 2020;45(6):30-32
Andrade C, Rao TSS. Prescription writing: Generic or brand? Indian J Psychiatry. 2017;59(2):133-7. DOI: https://doi.org/10.4103/psychiatry.IndianJPsychiatry_222_17
Downloads
Published
How to Cite
Issue
Section
